Skip to main content
Premium Trial:

Request an Annual Quote

Jason Gammack

Gene editing technology company Inscripta has appointed Jason Gammack as its first chief commercial officer. Gammack will design and oversee Inscripta's sales, marketing, business development, and customer support operations. He most recently served as vice president of Qiagen's life science business, where he led the development of the life science portfolio and go-to-market strategy. Prior to Qiagen, Gammack developed commercialization growth strategies at bioinformatics company Ingenuity Systems, which was acquired by Qiagen in 2013, and has also held senior leadership roles at Sigma-Aldrich, Life Technologies, Affymetrix, and Promega.  

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.